tbuckley/cabot-search huggingface dataset:
Myths About Cancer Lead To Workplace Discrimination
Authors: Julie A. Steele
Journal: JNCI Journal of the National Cancer Institute (1993)

Journal Article Myths About Cancer Lead To Workplace Discrimination Get access Julie A. Steele Julie A. Steele Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 85, Issue 2, 20 January 1993, Pages 92–93, https://doi.org/10.1093/jnci/85.2.92 Published: 20 January 1993
The new genetics: Genetic testing and public policy
Authors: N. A Holtzman, D. Shapiro
Journal: BMJ (1998)

This is the last of four articles discussing the broader implications of advances in genetics

The increasing rate of discovery of genes related to disease and the development of tests for them has fostered the idea that healthy people will be able to prevent future disease by undergoing genetic testing. The genetics of many diseases are such that tests have only a limited ability to predict the clinical outcome accurately. Nevertheless, the benefits of some predictive genetic tests can be substantial, such as screening newborns for phenylketonuria and sickle cell anemia and testing of older children at risk of familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2a.1 The fact remains that relatively few interventions have yet been devised to improve the outcome of most mendelian disorders.2 When no treatments are available, genetic testing can be used to avoid the conception or birth of affected offspring. Carrier screening in Sardinia, Cyprus, and elsewhere in the Mediterranean has led to an appreciable reduction in the birth of infants with thalassaemia through the use of prenatal diagnosis in couples at high risk and their selective termination of affected fetuses.3

Genetic testing (box), including prenatal testing, also carries the risks of inducing psychological sequelae4 and of making individuals vulnerable to discrimination and diminishing their privacy. Additional benefits of testing in refining clinical diagnosis and tailoring treatent may be in the offing,5 but these remain to be shown.

Both the American and British governments have recognised at least some of these problems, but solutions have been slow in coming. The United States started earlier to create a structure to consider the problems, but at present no federal committee is dedicated to addressing issues of genetic testing (box). In its final report, the Task Force on Genetic Testing reviewed …
Incidence of ifosfamide-induced neurotoxicity in lymphoma patients receiving fractionated ICE-based chemotherapy
Authors: H. Chow, C. H. Lim, W. Ong, H. J. Ng
Journal: Journal of Clinical Oncology (2004)

6677 Background: Ifosfamide-induced neurotoxicity is a treatment-related complication that is increasingly being reported. Here, we describe the incidence and presentation of neurotoxicity in our patients. Methods: We reviewed all Hodgkin's and Non-Hodgkin's lymphoma patients who received fractionated ICE (D1–3: ifosfamide 2g/m2 over 2h with an equivalent dose of mesna over 12h, carboplatin [AUC=5 divided equally between 3 days; max=800mg] over 1h, etoposide 75mg/m2 over 2h; cycles were repeated q28 days) +/- rituximab. Patients who experienced any neurologic symptom prior to initiation of chemotherapy were excluded. Results: Between July 2001 and May 2003, 19 patients received a total of 56 cycles. All had relapsed or refractory disease. Six patients presented with neurologic symptoms all on cycle 1 including 3 in whom dosage reductions were made. Of the 3 who went on to subsequent cycles, all with dosage reductions, 1 had a recurrent episode. Symptoms included one or more of the following: confusion (n=7), mood alterations (n=3), hallucinations (n=2), and somnolence (n=4). Of these, grade 3 toxicities occurred in 3 cases: confusion (n=1), hallucinations (n=1), and somnolence (n=1). There were no episodes of seizures. Symptoms were noted within 48–72h after the first dose of ifosfamide and in 6 of 7 cases resolved within 1–7 days. Treatment of symptoms involved the use of methylene blue alone in 2 cases and thiamine combined with methylene blue in 1 case. Previously identified risk factors such as renal and hepatic impairment, prior cisplatin, prior cranial radiation, albumin < 30g/L, pelvic/intra-abdominal involvement, and stage and type of disease were analyzed. Multivariate analysis identified renal impairment and low albumin as independent risk factors in our cohort. Concomitant use of rituximab was not identified as a risk. Conclusions: Fractionated ICE-based chemotherapy is associated with a high incidence of ifosfamide-induced neurotoxicity in relapsed or refractory lymphoma patients. No significant financial relationships to disclose.
INFLUENCE OF LEFT VENTRICULAR GEOMETRY AND BODY-SURFACE AREA ON MITRAL ANNULUS DIMENSIONS: ASSESSMENT BY COMPUTED TOMOGRAPHY
Authors: Philipp Blanke, Adam Berger, Nicolas Bilbey, Min Gao, Pascal Thériault Lauzier, Anson Cheung, Ye Jian, Chesnall Arepalli, Jasmine Grewal, Christopher Thompson, Robert Moss, Robert Boone, Nicolo Piazza, John Webb, Jonathan Leipsic
Journal: Journal of the American College of Cardiology (2015)
The Time-Varying Risk of Cardiovascular and Noncardiovascular Readmissions Early After Acute Myocardial Infarction
Authors: Umesh N. Khot, Michael J. Johnson, Ashley M. Lowry, Jeevanantham Rajeswaran, Samir Kapadia, Mehdi H. Shishehbor, Venu Menon, Stephen G. Ellis, Pamela Goepfarth, Eugene H. Blackstone
Journal: Journal of the American College of Cardiology (2017)
Abstract 5099: Identification of lung cancer biomarkers using lung cancer in female never smokers
Authors: Yun Gyu Park
Journal: Cancer Research (2011)

Abstract On a worldwide level, lung cancer in never smokers (LCINS) occupies 25% of total lung cancer incidence and this disease shows the 7th leading cause of cancer death. It is known that LCINS occurs frequently in asian women. It has been reported that 75% of female lung cancer occurred in never smokers in Republic of Korea. The clinico-pathological and molecular differences as well as geographic and gender variations between lung cancers in never smokers and smokers, indicate that two types of lung cancers should be regarded as a different disease entity. However, data for molecular understanding of LCINS are limited. We designed this study to identify the protein differentially expressed in lung cancer in female never smokers through proteomic analysis including 2-DE and MALDI-TOF-MS. To increase the probability of finding LCINS-associated proteins, the clinical specimens including sera and cancer tissues were classified as the following: normal female smokers, normal female never-smokers, lung cancer in female smokers, and lung cancer in female never smokers. Out of the proteins differentially expressed in LCINS tissues, levels of 10 proteins were increased and those of 8 proteins were decreased. Levels of 6 proteins were increased and those of 5 proteins were decreased in serum of patients with LCINS. The identified proteins were verified by performing Western blot analysis not only in the same sample used in proteomic analysis but also in samples obtained from lung cancer in female smokers. The serum protein, which was difficult to be identified in Western blotting, was verified by ELISA. Seven proteins identified in tissues and serum of patients with LCINS were verified by Western blot analysis and ELISA. These identified proteins might be applicable to biomarker development for diagnosis of LCINS and provide a more comprehensive understanding of tumor maintenance or progression. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 5099. doi:10.1158/1538-7445.AM2011-5099
Sodium Nitroprusside and Epidural Blockade in the Treatment of Ergotism
Authors: Poul K. Andersen, Kurt N. Christensen, Peter Hole, Bent Juhl, Tage Rosendal, Dag B. Stokke
Journal: New England Journal of Medicine (1977)

The treatment of vasospasm during ergotism has been difficult and unconvincing.1 2 3 A combination of hyperbaric oxygen and sympathetic blockade by means of continuous epidural anesthesia has been claimed to have some effect in limiting the ischemic peripheral gangrene induced by ergotism.4 Carliner and his co-workers1 reported a case of ergotism with extreme peripheral ischemia successfully and rapidly treated with continuous infusion of sodium nitroprusside. The two cases of ergotism presented below were treated with sodium nitroprusside in combination with continuous epidural anesthesia.Case ReportsCase 1 (Fig. 1). A 58-kg 44-year-old woman with a moderate intake of ergotamine owing to . . .
A7.04 IL-37: Therapeutic potential of a natural inhibitor of innate immunity during acute and chronic experimental arthritis
Authors: MI Koenders, G Cavelli, LA Joosten, PM van der Kraan, WB van den Berg, CA Dinarello
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background and objectives</h3> Recently characterised as a fundamental inhibitor of innate immunity and inflammation, member of the Interleukin (IL)-1 family IL-37 is highly expressed in the inflamed synovial tissue of patients with rheumatoid arthritis. We investigated the role of IL-37 in joint inflammation and the effects of IL-37 treatment on joint pathology in several mouse model of experimental arthritis. <h3>Materials and methods</h3> A strain of Bl/6 mice transgenic for human IL-37 (IL-37tg) was generated, and acute arthritis was induced by intra-articular delivery of streptococcal cell wall (SCW)-fragments. C57Bl/6 mice were also subjected to SCW-induced arthritis, and treated with a recombinant form of the naturally occurring human IL-37. Furthermore, chronic antigen-induced arthritis (AIA) was induced in IL-37tg mice by intra-articular delivery of methylated BSA as antigen, after systemic immunisation and booster with mBSA in FCA. Subsequently, DBA-1 mice with collagen-induced arthritis were treated with IL-37 recombinant protein. Arthritis development and histopathology of the joints were our first readout parameter. In addition, cytokine expression was determined in serum and synovial tissue. <h3>Results</h3> IL-37 gene expression in the synovium of IL-37tg mice reached peak levels in the resolution phase of acute SCW &nbsp;arthritis, thus not optimally exploiting the anti-inflammatory properties of IL-37. However, exogenously administered IL-37 effectively suppressed acute joint inflammation. This protective effect was associated with a decrease in synovial and systemic pro-inflammatory mediators, and with reduced recruitment of granulocytes to the inflamed joint. In line with this protective effect, mice transgenic for human IL-37 demonstrated suppressed joint swelling compared to wild-type control mice early after AIA induction. In addition, these IL-37tg mice had reduced synovial levels of IL-6 and KC, and showed a trend towards suppressed IL-17. Furthermore, exogenously administered IL-37 effectively suppressed arthritis incidence and disease severity during collagen-induced arthritis, thereby demonstrating the protective effects of IL-37 in both acute and chronic models of experimental arthritis. <h3>Conclusions</h3> IL-37 emerges as a key player in joint inflammation. The findings provide rationale for a protective role of IL-37 in the pathogenesis of arthritis, and imply a therapeutic potential for IL-37 administration.
Having your elective operation later in the week increases the risk of dying, research suggests
Authors: N. Hawkes
Journal: BMJ (2013)

The later in the week elective surgery takes place, the greater the chance of the patient dying, a study at Imperial College London has found.1

The research team found marked differences in death rates between days; deaths within 30 days of the operation were 44% higher if it occurred on a Friday rather than on a Monday (odds ratio 1.44, 95% confidence interval 1.39 to 1.50), and 82% higher if it occurred at the …
Bleeding angiodysplasia of the jejunum without a visible vessel
Authors: K. Hotta, K. Yoshida
Journal: Endoscopy (2009)

A 45-year-old man with melena and dyspnea on effort that had persisted for a week was admitted to our hospital. He had serious complications such as diabetic nephropathy and myocardial infarction, and was given an antiplatelet agent. His blood hemoglobin level dropped to 4.2 g/dl, but the vital signs were stable. He underwent esophagogastroduodenoscopy and colonoscopy on day 1 of hospitalization, but the bleeding source was not identified. He received blood transfusions for 5 days.
Abstract 2803: Disabeled-2 (Dab-2) modulates platelet-cancer cell interactions through its sulfatide binding domain.
Authors: Kaitlyn Andreano, Xiangping Fu, Daniel Capelluto, Carla Finkielstein
Journal: Cancer Research (2013)

Abstract Platelets’ role in cancer progression and metastasis has largely been attributed to platelet-mediated enhancement of tumor cell survival, extravasation (exiting form capillaries and entering organs), and angiogenesis. Correlations exist between the ability of some tumor cells to aggregate platelets in vitro and their metastatic potential in vivo that it is manifested as a hypercoagulable state found in most cancer patients. We have identified a tumor suppressor molecule (Dab-2) that it is released upon platelet activation and that modulates the extent of blood clotting. Our results show Dab-2 is released from alpha-granules in the platelet to the membrane surface where specifically binds to the integrin receptor, thus inhibiting platelet aggregation. Binding of Dab-2 to integrins is modulated by sulfatides, a form of glycosphingolipid that accumulate in platelet membrane and effectively compete for Dab-2 levels. Interestingly, we found that the N-terminal region of Dab-2 specifically binds to sulfatides through two conserved sulfatide-binding sites. Upon activation, sulfatides protect Dab-2 from thrombin cleavage, facilitate its internalization and modulate the surface expression of P-selectin, a coagulation protein needed for stabilization of platelet aggregates. P-selectin also mediates both tumor cell adhesion to vascular endothelial cells and the interaction between activated platelets and cancer cells (emboli) during metastasis. Interestingly, our data show that Dab-2/sulfatide recognition influences the stability of platelet aggregates heterotypically with cancer cells through sulfatide binding and, indirectly, by controlling P-selectin levels. Thus, we hypothesize that manipulation of Dab-2 function in response of platelet activation will impact emboli formation offering an alternative route for therapeutic strategies aimed to control metastatic processes. Citation Format: Kaitlyn Andreano, Xiangping Fu, Daniel Capelluto, Carla Finkielstein. Disabeled-2 (Dab-2) modulates platelet-cancer cell interactions through its sulfatide binding domain. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 2803. doi:10.1158/1538-7445.AM2013-2803
18F-FDG PET/CT in a Case of Parasite Infection Mimicking Lung and Breast Malignancy
Authors: Young Seok Cho, Doo Ryeon Chung, Joon Young Choi, Byung-Tae Kim, Kyung-Han Lee
Journal: Clinical Nuclear Medicine (2014)

A 51-year-old woman with dyspnea on exertion, fever, pleural effusion, and pericardial thickening underwent 18F-FDG PET/CT, which revealed focal hypermetabolic lesions in the right lung and left breast. The histopathology of the lesions was compatible with infiltration of inflammatory cells. Blood eosinophil counts were elevated, and enzyme-linked immunoassays were positive for antibodies to several parasites. After antiparasite medication, blood eosinophil counts were normalized, and PET/CT demonstrated complete disappearance of abnormal FDG accumulation in the lung and breast.
A Risk-Reduction Program for Patients With Peripheral Arterial Disease
Authors: William P. Robinson, Gilbert R. Upchurch
Journal: JAMA Surgery (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Larsen Syndrome
Authors: JOHN R. STY, DAVID C. GREGG, BRIAN E. LUNDEEN
Journal: Clinical Nuclear Medicine (1996)

Larsen syndrome is characterized by anomalies present at birth. These include a flat face, hypertelorism, cleft palate, cleft uvula, and laxity of joints with dislocations. In addition, there are central nervous system abnormalities, congenital heart defects, and neurological impairment due to cord compression. Not all anomalies may be present, and the condition is frequently under diagnosed. Our patient presented with right leg pain and limitation of motion of the right hip. The diagnosis of Larsen syndrome was not known. A radionuclide bone scan was performed to rule out an acute injury. The examination demonstrated extraosseous accumulation of tracer in the right thigh. An MRI scan showed edema involving the entire right sartorius muscle. This was secondary to repeated dislocations of the hip because of Larsen syndrome, which was established with genetic consultation.
Targeting Non-proteolytic Protein Ubiquitination for the Treatment of Diffuse Large B Cell Lymphoma
Authors: Yibin Yang, Priscilla Kelly, Arthur L. Shaffer, Roland Schmitz, Hee Min Yoo, Xinyue Liu, Da Wei Huang, Daniel Webster, Ryan M. Young, Masao Nakagawa, Michele Ceribelli, George W. Wright, Yandan Yang, Hong Zhao, Xin Yu, Weihong Xu, Wing C. Chan, Elaine S. Jaffe, Randy D. Gascoyne, Elias Campo, Andreas Rosenwald, German Ott, Jan Delabie, Lisa Rimsza, Louis M. Staudt
Journal: Cancer Cell (2016)
Isolation of Herpes-Simplex Virus from a Patient with Erythema Multiforme Exudativum (Stevens–Johnson Syndrome)
Authors: David W. Foerster, L. Vernon Scott
Journal: New England Journal of Medicine (1958)

HEBRA,1 in 1866, used the term "erythema multiforme exudativum" to describe a mild systemic disease of unknown etiology characterized by recurrent pleomorphic skin eruptions. Four years earlier Bazin2 had noted a similar syndrome associated with stomatitis and conjunctivitis. Stevens and Johnson,3 in 1922, reported 2 cases of a similar but more severe disease, in which there was a dramatic onset with fever, conjunctivitis and a cutaneous eruption. Illnesses like these have been described by such names as ectodermatosis erosiva pluriorificialis, erythema multiforme exudatorum, dermatostomatitis and erythema bullosum malignans.In 1950 Robinson and McCrumb4 pointed out the similarities in the clinical . . .
New legislation will ban sale of patients' data for commercial uses
Authors: Z. Kmietowicz
Journal: BMJ (2014)

England’s health secretary, Jeremy Hunt, has said that it will be illegal for patient information that is held by the government’s care.data programme to be sold to commercial organisations, such as insurance companies.

Hunt will put a raft of new measures on the statute books after the programme’s launch collapsed last month under the weight of sceptics’ arguments that data breaches and lack of security threatened patient confidentiality.

Hunt said that the new legislation would provide “rock solid assurance” to patients and doctors that information on patients collected by the care.data programme would be used only where there was a clear benefit to health or care and that data on patients who opted out of the scheme would not go to the Health and Social Care Information Centre, which is running the programme.

The new legislation will also create an expert advisory committee that will scrutinise decisions on releasing data, and the information centre …
The Genetic Mechanism of Idiopathic Hyperlipemia
Authors: Joseph D. Boggs, David Yi-Yung Hsia, Roland F. Mais, John A. Bigler
Journal: New England Journal of Medicine (1957)

IN 1932 Bürger and Grütz1 described a new clinical syndrome in children that was characterized by the following triad: sporadic attacks of acute abdominal pain; a xanthomatous type of skin lesion; and a fasting serum that was milky white. A total of 85 cases have now been reported from various parts of the world.1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 Children with idiopathic hyperlipemia usually first come to the attention of the physician because of peculiar attacks of abdominal pain. This is characterized by extreme tenderness, boardlike rigidity and sometimes collapse. These attacks are accompanied by fever, an increase in the neutrophil count and anorexia and . . .